Show simple item record

dc.contributor.authorMercurio, Arthur M.
dc.date2022-08-11T08:09:52.000
dc.date.accessioned2022-08-23T16:46:42Z
dc.date.available2022-08-23T16:46:42Z
dc.date.issued2019-01-23
dc.date.submitted2019-03-12
dc.identifier.citation<p>Int J Mol Sci. 2019 Jan 23;20(3):490. pii: ijms20030490. doi: 10.3390/ijms20030490. <a href="https://doi.org/10.3390/ijms20030490">Link to article on publisher's site</a></p>
dc.identifier.issn1422-0067 (Linking)
dc.identifier.doi10.3390/ijms20030490
dc.identifier.pmid30678134
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40932
dc.description.abstractThe function of vascular endothelial growth factor (VEGF) in cancer extends beyond angiogenesis and vascular permeability. Specifically, VEGF-mediated signaling occurs in tumor cells and this signaling contributes to key aspects of tumorigenesis including the self-renewal and survival of cancer stem cells (CSCs). In addition to VEGF receptor tyrosine kinases, the neuropilins (NRPs) are critical for mediating the effects of VEGF on CSCs, primarily because of their ability to impact the function of growth factor receptors and integrins. VEGF/NRP signaling can regulate the expression and function of key molecules that have been implicated in CSC function including Rho family guanosine triphosphatases (GTPases) and transcription factors. The VEGF/NRP signaling axis is a prime target for therapy because it can confer resistance to standard chemotherapy, which is ineffective against most CSCs. Indeed, several studies have shown that targeting either NRP1 or NRP2 can inhibit tumor initiation and decrease resistance to other therapies.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=30678134&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rights© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectVEGF
dc.subjectcancer stem cell
dc.subjectneuropilin
dc.subjectAmino Acids, Peptides, and Proteins
dc.subjectCancer Biology
dc.subjectCell Biology
dc.subjectCells
dc.subjectEnzymes and Coenzymes
dc.subjectNeoplasms
dc.titleVEGF/Neuropilin Signaling in Cancer Stem Cells
dc.typeJournal Article
dc.source.journaltitleInternational journal of molecular sciences
dc.source.volume20
dc.source.issue3
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4745&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3731
dc.identifier.contextkey14008330
refterms.dateFOA2022-08-23T16:46:42Z
html.description.abstract<p>The function of vascular endothelial growth factor (VEGF) in cancer extends beyond angiogenesis and vascular permeability. Specifically, VEGF-mediated signaling occurs in tumor cells and this signaling contributes to key aspects of tumorigenesis including the self-renewal and survival of cancer stem cells (CSCs). In addition to VEGF receptor tyrosine kinases, the neuropilins (NRPs) are critical for mediating the effects of VEGF on CSCs, primarily because of their ability to impact the function of growth factor receptors and integrins. VEGF/NRP signaling can regulate the expression and function of key molecules that have been implicated in CSC function including Rho family guanosine triphosphatases (GTPases) and transcription factors. The VEGF/NRP signaling axis is a prime target for therapy because it can confer resistance to standard chemotherapy, which is ineffective against most CSCs. Indeed, several studies have shown that targeting either NRP1 or NRP2 can inhibit tumor initiation and decrease resistance to other therapies.</p>
dc.identifier.submissionpathoapubs/3731
dc.contributor.departmentDepartment of Molecular, Cell and Cancer Biology
dc.source.pages490


Files in this item

Thumbnail
Name:
ijms_20_00490.pdf
Size:
427.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as © 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).